|
| |
PLIVA - Lachema a.s.PLIVA - Lachema a.s. was established according to the incorporation plan for the state enterprise Lachema and a licence from the Ministry of Industry naming the company the legal successor of the state enterprise Lachema on 27 March 1991. However, the company's history goes back much further. The Lachema Brno state enterprise started to manufacture and finish and pack pure, laboratory and specialty chemicals more than a half century ago. During 1950s Lachema became a major manufacturer of analytical reagents and indicators, dyes for microscopy, sugars, amino acids and a range of other chemicals and bio-chemicals.
| Contact Details: |
| Karásek 1 |
| |
| |
| 621 33 Brno, |
| Czech Republic |
| Tel: | 420 541 127 111 |
| Fax: | 420 541 127 634 |
| Email: | lachema@lachema.cz |
| WWW: | www.lachema.cz/
|
| |
Recent Publications by PLIVA - Lachema a.s.: |  |
Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts.
The oral anti-tumor activity of a novel platinum(IV) complex, coded as... | 28th June, 2006
| Research and Development, PLIVA-Lachema a.s., Brno, Czech Republic.
| Anticancer Drugs. 2006 Feb;17(2):201-6.
|
Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)].
The pharmacokinetics of total and free plasma platinum (Pt) and Pt tissue... | 27th April, 2005
| PLIVA-Lachema a.s., Brno, Czech Republic.
| Int J Pharm. 2005 Jan 6;288(1):123-9. Epub 2004 Nov 18.
DOI Direct Link |
Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines.
Procedure of the synthesis is described for new platinum(IV) drug LA-12... | 23rd March, 2004
| PLIVA-Lachema a.s., Karasek 1, 62133 Brno, Czech Republic.
| J Med Chem. 2004 Jan 29;47(3):761-3.
DOI Direct Link |
Press Releases on PLIVA - Lachema a.s.:
|
 |
| /C O R R E C T I O N -- Barr Pharmaceuticals, Inc. (NYSE: BRL)/ |
21st August, 2008 |
Barr Pharmaceuticals, Inc. |
In the news release, Barr Pharmaceuticals, Inc. (NYSE: BRL) Announces Barr
Announces Approval of Generic Aredia(R) Injection, 30mg/mL, 60mg/mL and
90mg/mL Injectable, issued yesterday, Aug. 20, by
|
| Barr Announces Approval of Generic Aredia(R) Injection, 30mg/mL, 60mg/mL and 90mg/mL Injectable |
20th August, 2008 |
Barr Pharmaceuticals, Inc. |
MONTVALE, N.J., Aug. 20 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals,
Inc. (NYSE: BRL) today announced that its subsidiary, PLIVA - Lachema a.s.,
has received final approval from the U.S. Food
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 586 times since April 2007, the link to the organisation's website has been followed 61 times Recent Search Terms used to find this page: pliva 562 | PLIVA LACHEMA | Lachema | R D Pliva-Lachema a.s. | reagents companies in Brno Czech republic | lachema september 2009 | lachema brno | lachema-Brno | lachema-Brno | Pliva Lachema | . This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for PLIVA - Lachema a.s. |
